Regulators in Finland threatened to fine Novartis (NVS) for violating laws governing the distribution of prescription medicines through pharmacies and state-owned hospitals.
The Finnish Medicine Agency took the drug maker to task for allowing the Aimovig migraine drug to be made available at a reduced price to patients through hospitals on an outpatient basis, instead of through pharmacies. Another violation involved an attempt to limit patients who would have been eligible for the medicine at a reduced price, although further details were not disclosed.
About the Author Reprints
